SREBF1 and non-small cell lung carcinoma: The PI3K-AKT pathway, a key driver of NSCLC, not only promotes tumor growth but also suppresses ferroptosis by enhancing lipid metabolism and antioxidant defense through mechanisms such as SREBP1/SCD1-mediated lipogenesis (43).